PlGF-MMP9-engineered iPS cells supported on a PEG-fibrinogen hydrogel scaffold possess an enhanced capacity to repair damaged myocardium by C. Bearzi et al.
OPEN
PlGF–MMP9-engineered iPS cells supported on
a PEG–fibrinogen hydrogel scaffold possess
an enhanced capacity to repair damaged myocardium
C Bearzi1,2, C Gargioli1, D Baci1, O Fortunato1, K Shapira-Schweitzer3, O Kossover3, MV G Latronico4, D Seliktar3, G Condorelli4
and R Rizzi*,1,2
Cell-based regenerative therapies are significantly improved by engineering allografts to express factors that increase
vascularization and engraftment, such as placental growth factor (PlGF) and matrix metalloproteinase 9 (MMP9). Moreover, the
seeding of therapeutic cells onto a suitable scaffold is of utmost importance for tissue regeneration. On these premises, we
sought to assess the reparative potential of induced pluripotent stem (iPS) cells bioengineered to secrete PlGF or MMP9 and
delivered to infarcted myocardium upon a poly(ethylene glycol)–fibrinogen scaffold. When assessing optimal stiffness of the
PEG–fibrinogen (PF) scaffold, we found that the appearance of contracting cells after cardiogenic induction was accelerated on
the support designed with an intermediate stiffness. Revascularization and hemodynamic parameters of infarcted mouse heart
were significantly improved by injection into the infarct of this optimized PF scaffold seeded with both MiPS (iPS cells engineered
to secrete MMP9) and PiPS (iPS cells engineered to secrete PlGF) cells as compared with nonengineered cells or PF alone.
Importantly, allograft-derived cells and host myocardium were functionally integrated. Therefore, survival and integration of
allografts in the ischemic heart can be significantly improved with the use of therapeutic cells bioengineered to secrete MMP9
and PlGF and encapsulated within an injectable PF hydrogel having an optimized stiffness.
Cell Death and Disease (2014) 5, e1053; doi:10.1038/cddis.2014.12; published online 13 February 2014
Subject Category: Experimental Medicine
The use of cell-based protocols for regenerative medicine in
cardiology is hindered by the complexity of obtaining a reliable
source of functional cardiomyocytes (CMs)1 and by the low
survival rate of allografts within recipient myocardium.2
Regarding the first point, induced pluripotent stem (iPS) cells
are a very promising source of stem cells that are relatively
easily generated by the reprogramming of adult somatic cells,
such as fibroblasts, and that can be differentiated into all cell
types of the body, including CMs.3,4 We have previously
reported that iPS cells can be generated – through the
conventional ‘Yamanaka approach’ – from still-replicating
1-day-old mouse CMs, and that these cells more efficiently
differentiate into cardiac progenitors than iPS cells generated
from other cell types: in fact, the efficiency of cardiogenic
differentiation of CM-derived iPS cells was 53–57% compared
with 33–39% for mouse embryonic stem cells and 25–33% for
cardiac fibroblast-derived iPS cells.5 However, how stem cells
adapt to a hostile environment, such as the postinfarct
myocardium, and whether they efficiently differentiate after
engraftment toward the CM lineage, overcoming survival
stresses, is not known.6
On the second point, survival of engrafted cells within
damaged myocardial tissue is critically dependent upon
support by an adequate blood supply. We have demonstrated
that the survival of cell allografts within muscle can be
improved by bioengineering them to express specific factors:
in fact, when engrafted in a model of muscle dystrophy,
mesangioblast stem cells forced to secrete placental growth
factor (PlGF)7,8 and matrix metalloproteinase 9 (MMP9)9
produced significant improvements in muscle performance.10
PlGF is a well-known angiogenic factor that enhances
neoangiogenesis and that attracts host vessels.11 It has a
higher disease-specific activity than other angiogenic factors,
such as vascular endothelial growth factor (VEGF) and other
cytokines, and therefore does not affect quiescent vessels in
healthy tissues. As a consequence, PlGF is an attractive
therapeutic tool for treating ischemic diseases.12 Moreover, in
the context of acute myocardial infarction (AMI), the genera-
tion of scar tissue hinders the revascularization process.
Secretion by the allograft of MMP9 – an enzyme that
breaks down scar tissue and, thus, permeabilizes the
extracellular matrix (ECM), remodeling tissues in pathological
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processes9,13 – overcomes this limitation by creating an
environment conducive to the migration of resident and/or
circulating stem cells.13
Another fundamental aspect that improves the survival of
cell allografts and, hence, the repair of damaged tissue, is the
presence of a biomimetic scaffold onto which the therapeutic
cells can be seeded. Biomaterial scaffolds can protect
transplanted cells, preventing cell death by improving
proliferation and/or reducing apoptosis. Different types of
biomaterials constructed from polymers or copolymers of
natural or synthetic origin have been used for engrafting cells
in the myocardium.14,15 Among these, hydrogels are being
increasingly used to mimic the natural ECM in three-
dimensional (3D) scaffolds.16,17 A semisynthetic hydrogel
composed of a fibrinogen backbone crosslinked with bifunc-
tional poly(ethylene glycol) (PEG) side chains was previously
used by our group for cardiac and skeletal muscle regenera-
tion. The PEG–fibrinogen (PF) hydrogel was used to make 3D
cellularized hydrogel constructs by seeding cells into a liquid
solution of PF containing a photoinitiator. Exposure to long-
wavelength UV light initiates polymerization of the scaffold.
This type of hydrogel has a distinct advantage over other
types of scaffold because its mechanical properties are highly
malleable while leaving the functionality of the encapsulated
cells well preserved by the backbone of the polymeric
network. In fact, the biological domains in the fibrinogen
backbone provide attachment motifs for endothelial and
smooth muscle cell adhesion necessary for the development
of a blood supply and of newly formed tissue, as well as
proteolytic sensitivity to cell-mediated biodegradation.16,17
Moreover, the shear storage modulus (G0) of the PF scaffold –
which is dependent upon the molecular weight of the PEG
constituent, and is proportional to the percent polymeric
composition and crosslinking – can be altered to suit the
characteristics of the recipient tissue and the donor cells.
Thus, a feasible strategy to overcome poor allograft survival
in cardiac muscle reconstruction would consist of a combina-
torial approach comprising the bioengineering of therapeutic
cells so that they express factors that facilitate vasculariza-
tion, and the delivery of these cells on a support optimized for
the damaged myocardium. For the present report, we
employed iPS cells generated from 1-day-old mouse CM –
because they represent an efficient model with which to study
myocardial regeneration – that we transduced with lentiviral
vectors encoding MMP9 or PlGF. We then assessed the
capacity of these bioengineered iPS cells to aid myocardial
repair in an AMI mouse model, by injecting them into infarcts
as part of a cell-seeded PF hydrogel construct.
Results
Characterization of bioengineered iPS cells. After
ascertaining that bioengineered iPS cells were capable of
synthesizing PlGF and MMP9 (Figure 1a and Supplementary
Figure 1 online), we examined the biological activity of the
secreted factors. For MMP9, we used a cell invasion assay to
measure the migratory capacity of iPS cells stimulated by a
chemoattractant, either stromal cell-derived factor-1 (SDF-1)
or stem cell factor (SCF): MMP9-secreting iPS (MiPS) cells
were significantly better able to digest the matrigel barrier
and migrate into the lower compartment of a Boyden
chamber than control iPS cells (Figures 1b and c).
The biological activity of PIGF was assessed by analyzing
the number and the length of capillary-like structures
formed by human umbilical vein endothelial cells (HUVECs)
exposed to conditioned media: HUVECs grown in a condi-
tioned medium from PlGF-secreting iPS (PiPS) cells had a
significantly enhanced angiogenic capacity with respect to
those kept in medium originating from control iPS cell
cultures (Figures 1d and e).
In vitro biocompatibility of iPS cell–scaffold constructs.
We then assessed the effect of culturing iPS cells with the PF
scaffold using the matrix stiffness to optimize either survival
or cardiac differentiation. The iPS cells – as for embryonic
stem cells – must be cultured on a mouse embryonic
fibroblast (MEF) feeder layer to prevent them from
differentiating. We examined stiffness-optimized PF scaffolds
supporting iPS cell cultures as an alternative to MEF feeder
layers. In addition, modulation of PF stiffness was used to
optimize 3D cardiac muscle tissue formation in vitro
using dispersed encapsulated iPS cells. PEG–diacrylate
(PEG–DA) crosslinker was added to the PF in order to
increase its stiffness while maintaining iPS cell stemness
and/or facilitating cardiac differentiation.18 To this end, three
different scaffold compositions were examined: PF without
any additional crosslinker, a low stiffness (G0B120Pa)
composition; PF plus an additional 1% PEG–DA, an
intermediate stiffness (G0B350Pa) composition; and PF
plus an additional 2% PEG–DA, a high stiffness (G0B700Pa)
composition.18,19
We did not observe any effect of increasing stiffness on iPS
cell proliferation: in fact, no morphological differences were
discernible in iPS cell colonies cultured on MEF or on either of
the three scaffold compositions (Figure 2a). Importantly, iPS
cell lines were still capable of growing and maintaining their
undifferentiated state when cultured on a PF scaffold in the
absence of a feeder layer. Quantitative real-time-PCR
(qRT-PCR) demonstrated that the expression of the stem
cell markers Oct4, Sox2, and Nanog remained stable and
long-lasting when iPS cells were grown on the PF hydrogels,
and was comparable to iPS cells cultured on MEF (Figure 2b,
Supplementary Table 1 online). Culturing on the hydrogel had
the additional advantage of increasing cell purity by removing
contamination by MEF. Immunofluorescence staining for
the embryonic antigen stage-specific embryonic antigen 1
(SSEA1) confirmed stemnessmaintenance of all iPS cell lines
after 14 days of culture on PF supplemented with an additional
1% PEG–DA (Figure 2c).
We then investigated the cardiac differentiation capacity of
dispersed iPS cell lines in 3D culture. To this end, we used a
differentiation protocol consisting of a defined concentration of
bone morphogenetic protein 2 (BMP2),5,20 induction of
embryoid bodies (EBs), and then encapsulation in PF. We
found that EBs cultured in the intermediate-stiffness composi-
tion (i.e., PF enriched with an additional 1% PEG–DA) started
beating 1 day earlier than those cultured with the standard
protocol – in which EBs are plated on gelatinized dishes – or
on the other two scaffold compositions (Supplementary Video
1 online). qRT-PCR revealed that EBs encapsulated in the PF
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Figure 1 Characterization of iPS cells bioengineered to express MMP9 or PlGF. (a, left) RT-PCR showing the presence of an MMP9 transcript in iPS cells bioengineered
to secrete MMP9 (MiPS) into the culture medium; (a, right) RT-PCR illustrating that the PlGF transcript was produced by iPS cells engineered to secrete PlGF (PiPS). iPS cells
transduced with an nLacZ viral vector (iPS) were used as a negative control. (b) Cell invasion experiments attested an enhanced aptitude of MiPS cells, with respect to control
iPS cells, to permeabilize the matrix and migrate when attracted by either SCF or SDF-1. The graph gives the number of invading cells/field on the y axis. BSA (bovine serum
albumin) was used as the control condition. Mean±S.E.M.; N¼ 3. (c) Representative images of DAPI-stained nuclei in invasion experiments. iPS and MiPS cells were
stimulated to migrate through a matrigel membrane by either SCF or SDF-1. Magnification  20; white bars¼ 20mm. (d, left) Number of capillary-like structures generated by
HUVECs after exposure to conditioned media; (d, right) length of the newly formed capillaries after exposure to conditioned media. Mean±S.E.M.; N¼ 3. (e) Representative
images of capillary-like structures formed by HUVECs after exposure to control iPS- or PiPS cell-conditioned media. Magnification  5; white bars¼ 100mm
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hydrogel compositions maintained a higher expression of
early (Brachyury) and late (Mhy6) cardiac genes (Figure 3a
and Supplementary Figure 2 and Supplementary Table 1
online). The long-lasting expression of the genes responsible
for the extreme phases of cardiomyogenesis (i.e., Brachyury
and Mhy6) led us to speculate that the intermediate-stiffness
composition promoted a more stable differentiation process in
iPS cells when in 3D culture, and resulted in a higher rate of
cell maturation.
We used qRT-PCR to quantitatively define the relationship
between the intermediate-stiffness PF scaffold and the
increased pattern of CM differentiation. Surprisingly, we found
that encapsulation in this PF hydrogel composition signifi-
cantly affected genes involved in apoptosis: in fact, the
expression of apoptotic genes (caspase 3, Bcl2, and p21) was
significantly decreased (Figure 3c), whereas proliferation
genes (cyclins D1 and E1) were unaffected (Figure 3b and
Supplementary Table 1 online). Immunofluorescence assays
confirmed the expression of the cardiac antigen a-sarcomeric
actin (a-Sarc) after 3, 5, and 7 days of differentiation of PiPS
cells encapsulated in the intermediate-stiffness scaffold
(Figure 3d).
Biocompatibility of iPS cell–scaffold constructs in vivo.
We have previously demonstrated that with respect to other
cell types, iPS cells generated from neonatal CMs have an
enhanced efficiently for redifferentiation into CMs.5 Because
growth and maturation of cells are improved by 3D culture
procedures, we tested the biocompatibility and differentiation
capacity of our model in vivo. Accordingly, constructs
consisting of 20 ml of polymerized intermediate-stiffness
scaffold encapsulating either 1 106 PiPS or iPS cells at 5
days of differentiation were introduced onto the surface of
tibialis anterior (TA) muscle of immunodeficient mice.
One month after subcutaneous implantation, any newly
formed structures were removed and analyzed with histology
and FACS.
Constructs seeded with differentiated PiPS cells generated
larger structures with less necrosis than those prepared with
differentiated control iPS cells (Figure 4a, left panels).
Moreover, these structures contained cells that were positive
for a-Sarc and a-smooth muscle actin (a-SMA; Figure 4a,
middle and right panels). The latter cells formed arteriolar-like
structures, indicative of arteriogenesis. The exogenous nature
of these cells was attested by positivity for nLacZ. Some of
these newly formed structures were removed from the mice
and enzymatically digested, and the isolated cells cultured on
gelatinized dishes.We observed that cultures contained small
foci of beating cells (Supplementary Video 2 online). FACS
analysis for cardiac troponin I (cTNNI) and b-galactosidase
(b-gal) determined that a higher number of LacZ-positive cells
were co-positive for cTNNI in structures generated from PiPS
cells (Figure 4b). Moreover, a higher vessel density was found
in tissue generated from differentiated PiPS cells (Figure 4c).
iPS cell–scaffold constructs in an AMI mouse model.
The effect of the implant was then studied in a model of AMI.
Female NOD-SCID mice had their left descending coronary
artery surgically ligated to produce an ischemic area in the
left ventricle. Implants prepared from intermediate-stiffness
Figure 2 Effect of growing iPS cells on PEG–fibrinogen scaffolds. (a) Morphology of iPS, MiPS, and PiPS cell colonies cultured on mouse embryonic fibroblast (MEF)
feeder layers (upper row), on PEG–fibrinogen (PF) scaffolds without a feeder layer (second row), or on PF supplemented with additional (1 and 2%) PEG–diacrylate
(PEG–DA) in the absence of MEFs (lower two rows). White bars¼ 100mm. (b) qRT-PCR attesting the expression of three embryonic genes after 7 days and 14 days of
culture. iPS, MiPS, and PiPS cells maintain their pluripotent status when grown on MEF (CNTR MEF), PF, or 1 and 2% PEG–DA-enriched PF. Bar graphs express DDCt
values. Mean±S.E.M.; N¼ 4. (c) Immunofluorescence for SSEA1 in iPS, MiPS, and PiPS cells after 14 days of culture on PF supplemented with an additional 1% PEG–DA.
Nuclei were stained with DAPI. White bars¼ 100 mm
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scaffolds seeded with iPS cells generated from male mice
were then immediately injected into the ischemic myo-
cardium of the female mice. PF alone was injected either
into the border zone or into the infarct to evaluate the
supporting functions of the scaffold after the ischemic event.
The presence of allograft cells was ascertained by
fluorescent in situ hybridization for the Y chromosome
(Figure 5a). Importantly, male-derived iPS cells were able to
integrate functionally with the female host tissue. Gap-
junction formation – identified as positivity for connexin 43
(CNX43) – was found between allograft and host cells.
Moreover, the data suggested that the muscle origin of the
grafted iPS cells may have facilitated transdifferentiation into
SMA-positive cells that are necessary for the development of
a blood supply to the infarcted area.
Histological analysis highlighted an increase in capillary
density and angiogenesis, and a decrease in fibrotic and
apoptotic indexes, in AMI mice receiving the various iPS cell–
PF implants as compared with controls (Figure 5b). Apoptosis
was also markedly reduced in mice treated only with the
scaffold, confirming previous results in this direction.
The mice were also monitored for 30 days to assess
hemodynamic parameters. Percent fractional shortening
(%FS) was drastically reduced in the PBS control group 30
days after AMI (21±1%), whereas mice treated with iPS cells
only (30.3±1.3%), scaffold only (25±1.1%), or with the iPS
cell–scaffold construct (32.3±3.5%) had relatively slower
time-dependent reductions in this parameter. On the other
hand, treatments conducted with engineered iPS cells
produced a partial recovery of cardiac function (MiPS cell–
scaffold, 31±3%; PiPS cell–scaffold, 34±1%), whereas the
combined use of MiPS with PiPS cells within the scaffold
produced the best therapeutic outcome (37±1.8%;
Figure 5c). The velocity/time integral (VTI) – which reflects
Figure 3 Gene expression in iPS cell lines seeded onto PF scaffolds with differing stiffnesses. (a) qRT-PCR was used to assess expression of early (Brachyury and Tbx5),
intermediate (Nkx2.5 and Gata4), and late (Mhy6 and cTnnI) cardiac genes 7 days after differentiation. (b) qRT-PCR for the expression of genes related to proliferation
(Ccnd1, p53, and Ccne1). (c) qRT-PCR assays for the expression of genes related to apoptosis (Csp3, Bcl2, and p21). In (a–c), controls are represented by undifferentiated
iPS cells (CNTR) and by differentiated iPS cells cultured on gelatin (iPS). *Po0.05, **Po0.01 versus iPS cells. Bar graphs express mean DDCt values±S.E.M.; N¼ 4
(a–c). (d) Immunofluorescence for the cardiac proteins a-sarcomeric actin (a-Sarc, red) and connexin 43 (CNX43, green) after 3, 5, and 7 days of differentiation in PiPS cells
seeded onto a PEG–fibrinogen (PF) scaffold stiffened with an additional 1% PEG–diacrylate (PEG–DA). Nuclei were stained with DAPI (blue). White bars¼ 200mm (for day 3)
and 100mm (for days 5 and 7)
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the velocity of blood flow in the left ventricular outflow tract in
the designated time span – was nearly restored to physiologic
values after 1 month in the MiPSþPiPS cell–scaffold group.
Detailed analysis of the results revealed that the biomaterial
seeded with both engineered cell types was the only that
produced a marked improvement after 30 days of adminis-
tration (Supplementary Figure 3 online). A representative
infarcted mouse heart with a regenerated area (rectangle) is
given in Figure 5d.
Taken together, these results underscore the efficacy of
using a combined approach – that is, implantation of a
biomaterial seeded with bioengineered cells – for the
generation of functional cardiac tissue to prevent adverse
cardiac remodeling.
Discussion
We report here for the first time an approach for the in vivo
cardiogenic differentiation of PF–hydrogel-encapsulated iPS
cells. Our data demonstrate that a PEGylated fibrinogen
scaffold, optimized for stiffness through the use of additional
PEG–DA crosslinker, promoted and accelerated cardiac
differentiation of iPS cells. In addition, graft vascularization
was enhanced by engineering iPS cells to produce PlGF,
whereas the secretion of MMP9 improved engraftment by
decreasing scar formation. This combination increased the
survival of engrafted cells when injected into the heart of a
mouse model of myocardial infarction, and led to less
ischemic damage. In fact, %FS and systolic and diastolic
functions were significantly improved in comparison with the
other treatment conditions tested in this study.
Several studies and preclinical surveys have reported
reduced graft retention – and hence poor and unsatisfactory
recovery – because of a very low survival rate of therapeutic
cells when these are used alone.1,2,21 Increasing emphasis
has therefore been placed on the use of biomaterials in
combination with cells as a means of improving graft retention
and survival. Recent attempts at restoring cardiac tissue
function have used such combinations in addition to modula-
tion of the biomaterial features in order to design cell-delivery
systems that are biocompatible, biofunctional, bioactive, and
reabsorbable, ensuring optimal cell–matrix interactions and
Figure 4 Subcutaneous implantation of PF scaffolds seeded with differentiated, bioengineered iPS cells in mice. (a, left) Extracardiac muscle generated from
PEG–fibrinogenþ 1% PEG–diacrylate (PFþ 1% PEG–DA) scaffolds seeded with iPS (upper panel) or PiPS (lower panel) cells after 15 days from implantation in
immunodeficient NOD-SCID mice; (a, middle and right) immunofluorescence assays demonstrating the presence of a-sarcomeric actin (a-Sarc), indicative of the presence of
cardiomyocytes, and a-smooth muscle actin (SMA), indicative of the presence of vessels, inside the neo-formed tissue. The exogenous origin of the cardiomyocytes and
vessels was proven by nuclear expression of nLacZ. The nuclei were stained with DAPI. White bars¼ 100mm. (b) FACS analysis scatter plots presenting the percentages of
b-galactosidase (b-Gal) and cardiac troponin I (cTNNI) double-labeled cells isolated from the newly formed structures by digestion. Mean±S.E.M.; N¼ 4. (c) Graph of vessel
density within the tissue formed by iPS or PiPS cells. Mean±S.E.M.; N¼ 4
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cell signaling.22–25 Fundamentally, this approach entails
recreating the most accurate environment mimicking the
cardiac ECM. The structural molecular signals, and the
biofeedback associated with the cell–biomaterial interface,
must work together to drive the transplanted cells toward a
desired and stable phenotype. The control of cell behavior
with the use of biomaterials was addressed recently through
the presentation of immobilizedmolecules and cellular signals
Figure 5 Cardiac implantation of PF scaffolds seeded with differentiated, bioengineered iPS cells in infarcted mice. (a, upper) Representative immunofluorescence image
demonstrating the exogenous origin, that is, Y-chromosome positivity (white), of newly formed, a-sarcomeric actin-positive cardiomyocytes (a-Sarc, red) in a female ischemic
heart injected with PFþ 1% PEG–DA seeded with both MiPS and PiPS cells deriving from a male mouse. Connexin 43 (CNX 43) expression in yellow; (a, lower)
immunofluorescence image of an exogenous (Y chromosome positive) cell (white) contributing to the formation of a-smooth muscle actin-positive vessel (SMA, red) in female
ischemic cardiac tissue (a-Sarc, green) injected with PFþ 1% PEG–DA scaffold seeded with both MiPS and PiPS cells derived from a male mouse. Nuclei were stained with
DAPI (blue). In both images, arrows indicate some of the positive cells. White bars¼ 100mm; higher magnification views are given in the rectangles. (b) Histological analysis
of capillary density, fibrotic index, angiogenesis, and apoptotic index. iPS, MiPS, PiPS, and MiPS plus PiPS cells were encapsulated in PEG–fibrinogen (PF) supplemented
with an additional 1% PEG–DA and injected into ischemic myocardium after coronary ligature. Control groups were injected with iPS cells resuspended in PBS, with PBS only,
or with PF only. (c) Echocardiographic analysis: percent fractional shortening (%FS), left ventricular posterior wall diameter in diastole (LV PWd), and left ventricular velocity/
time integral (LV VTI). Effects of iPS, MiPS, PiPS, and MiPS plus PiPS cells seeded onto PFþ 1% PEG-DA and injected after coronary occlusion; control groups received
PBS, iPS cells resuspended in PBS, or PF without cells. Boxes represent 95th percentile; *Po0.05, **Po0.01 versus PBS. Mean±S.E.M.; N¼ 4 (b and c).
(d) Representative image of an ex vivo infarcted female heart injected with male MiPS and PiPS cells supported on a PFþ 1% PEG-DA scaffold at 30 days after left coronary
artery ligature (arrow)
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from the substrate, as well as mechanically stressed cellular
environments.26–28
Using the PF hydrogel properties, including optimization of
its stiffness, we designed and investigated a 3D encapsulating
environment that can be used for cultivating CMs derived from
iPS cells. Unlike naturally derived fibrinogen hydrogels, a
combination of PEG and fibrinogen was found to improve the
mechanical stability of the scaffold so as to tolerate the high
repetitive stresses and proteolytic activity of the ischemic
myocardium, and, importantly, to prevent cardiac remodeling
and scar expansion.
iPS cell-based strategies hold great potential for future
clinical application, but we are still far from translating them to
the clinic. More basic research needs to be undertaken, for
instance to find the most appropriate stage of differentiation
for grafting iPS cells. In fact, because iPS cells pass through
multiple stages of differentiation before becoming functionally
mature CMs, implanting iPS cell-derived cells that are too
immature may risk generating cells that are not the required
type or that develop into tumors. On the other hand, if
engrafted when toomature, theymight not be adaptable to the
surrounding environment and, hence, conducive to improving
cardiac function. Moreover, although the prospective of using
cardiomyocyte-derived iPS cells for clinical applications is
negligible, they do provide an optimal system with which to
study and develop myocardial repair strategies.
Materials and Methods
Lentiviral transduction. Cardiac-specific lentiviral vectors carrying Oct4,
Sox2, KIf4 (OSK), nLacZ, PlGF, or MMP9 were generated with a standard
procedure.5,11 Neonatal mouse cardiomyocytes were isolated from 1-day-old mice
and reprogrammed with OSK to generate iPS cells as previously reported.5 iPS
cells were transduced with lentiviral vector carrying nLacZ and used as a control,
or with those carrying PlGF or MMP9 to generate PlGF- and MMP9-secreting cells
(respectively termed PiPS and MiPS cells). iPS cells were then redifferentiated into
cardiomyocytes by exposure to 2.5 ng/ml BMP2 and induction of EB formation via
the hanging-drop culture method.5
Biomaterial preparation. PEG-fibrinogen (PF) and the PEG–DA crosslinker
were prepared as described previously.18,29,30 Briefly, PF was prepared at a
desired concentration and diluted with sterile PBS as required. To increase the
stiffness of the scaffold, an additional 1 or 2% PEG–DA was added to the basic
PF mixture in some cases. The photoinitiator Irgacure 2959 (Ciba Specialty
Chemicals, Basel, Switzerland) was added to the PF at a final concentration of
0.1% w/v. Cells were added at the desired concentration and the solution
immediately exposed to UV light to initiate polymerization within glass tubes.
Invasion and angiogenic assays. The Boyden chamber assay was used
to assess the migratory potential of cells when stimulated with either 100 ng/ml
SDF-1 or 100 ng/ml SCF. In vitro capillary formation was assessed in HUVECs
stimulated with conditioned media from iPS cell cultures. qRT-PCR, histology,
FACS analysis, immunofluorescence microscopy, and echocardiography were all
done using standard techniques.
Subcutaneous implantation of constructs in mice. Cylindrically
shaped PF plugs encapsulating either 1 106 iPS or PiPS cells and polymerized
in vitro were implanted underneath the skin of NOD-SCID mice at the level of the
TA muscle. Mice were killed 2 weeks after the implantation, and growths found on
the TA muscle collected.
AMI mouse model and intrainfarct implantation of constructs.
The left descending coronary artery of female NOD-SCID mice was surgically
ligated in order to produce an ischemic area in the left ventricle. iPS, MiPS, or
PiPS (5 105) cells, all generated from male mice, were resuspended separately
or in combination with hydrogels just before use and injected into the ischemic
area right after the ligation. The combinations were: iPS cells encapsulated in PF
supplemented with an additional 1% PEG-DA (PFþ 1% PEG–DA); MiPS cells
encapsulated in PFþ 1% PEG-DA; PiPS cells encapsulated in PFþ 1% PEG-DA;
and MiPSþ PiPS cells in PFþ 1% PEG-DA. PF without iPS cells was injected
either into the border zone or into the infarcted area to evaluate the supporting
functions of the scaffold after the ischemic event in a control group. The presence
of functional tissue together with its effects on cardiac function was evaluated by
immunofluorescence, histological assays, and echocardiography.
Statistical analysis. Linear-model two-way repeated measures ANOVA was
used to confirm the differences in over-time-dependent surveys. One-way ANOVA
was used to evaluate the variations in percentage of regenerated areas and
grafted cells between experimental groups and the control. All results are
expressed as mean±S.E.M. Student’s t-test was used to confirm the differences
between the best proposed approach and the other groups.
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